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A  quantitative  method  is presented  to rank  strengths,  weaknesses,  opportunities,  and  threats  (SWOT)  of
modiﬁed vaccinia  virus  Ankara  (MVA)  as  a  platform  for pre-pandemic  and pandemic  inﬂuenza  vaccines.
Analytic  hierarchy  process  (AHP)  was  applied  to  achieve  pairwise  comparisons  among  SWOT  factors  in
order to prioritize  them.  Key opinion  leaders  (KOLs)  in  the  inﬂuenza  vaccine  ﬁeld were  interviewed  to
collect  a  unique  dataset  to evaluate  the  market  potential  of this  platform.
The purpose  of  this  study,  to evaluate  commercial  potential  of the  MVA  platform  for the  development
of  novel  generation  pandemic  inﬂuenza  vaccines,  is  accomplished  by using  a SWOT  and  AHP combined
analytic  method.  Application  of  the  SWOT–AHP  model  indicates  that  its strengths  are  considered  more
important  by  KOLs  than  its  weaknesses,  opportunities,  and  threats.  Particularly,  the  inherent  immuno-
genicity  capability  of  MVA  without  the  requirement  of an adjuvant  is the  most  important  factor  to  increase
commercial  attractiveness  of  this  platform.  Concerns  regarding  vector  vaccines  and  anti-vector  immu-
nity are considered  its  most  important  weakness,  which  might  lower  public  health  value  of  this  platform.
Furthermore,  evaluation  of the  results  of  this  study  emphasizes  equally  important  role  that  threats  and
opportunities  of  this  platform  play.
This study  further  highlights  unmet  needs  in  the  inﬂuenza  vaccine  market,  which  could  be addressed  by
the  implementation  of the  MVA  platform.  Broad  use  of MVA  in clinical  trials shows  great  promise  for  this
vector  as  vaccine  platform  for pre-pandemic  and  pandemic  inﬂuenza  and  threats  by other  respiratory
viruses.  Moreover,  from  the  results  of the  clinical  trials  seem  that MVA  is  particularly  attractive  for
development  of vaccines  against  pathogens  for which  no,  or only  insufﬁciently  effective  vaccines,  are
available.
ublis© 2015  The  Authors.  P
. Introduction
Vaccines are the most cost-effective tools for controlling the
pread and impact of infectious diseases in both humans and ani-
als [1]. Vaccines generally work by harnessing the host’s adaptive
mmune system against infectious pathogens, by exposing it to
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an inactivated, live-attenuated, sub-unit or recombinant version
of the wild-type pathogen or parts thereof [2,3]. Furthermore,
appropriately managed vaccination campaigns have completely
eradicated two devastating infectious diseases of humans and
animals: smallpox and rinderpest, respectively. This accomplish-
ment has not been equalled by any other medical or veterinary
interventions [4–6]. Unfortunately, interventions for most viral
diseases still represent a signiﬁcant unmet medical need. Rea-
sons include, but are not limited to absence of safe and effective
vaccines, lack of vaccine availability, accessibility, and affordabil-
ity [2]. State-of-the-art technologies may  be used to overcome
at least some of these limitations. This paper largely focuses
on the issue of vaccine availability to combat human pandemic
inﬂuenza.
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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learn more about the industrial players in the market, and develop
a validated set of interview questions. Market potential of a new
production platform for inﬂuenza vaccine development, such as
MVA, is best evaluated by KOLs specialized in the ﬁeld of inﬂuenza
Table 1
Study design. SWOT: strengths, weaknesses, opportunities and threats.
STEP 1 STEP 2 STEP 3
Literature review and
interview
SWOT–AHP application Conclusion, data
integration
•  Relevant background
information
• Insights into market
competition
•  Interviews • Results from previous
steps are integrated
and illustrated in a
SWOT  matrix
Data analysis Data analysis Visualization
•  Develop set of
interview questions
• Determine SWOT main
groups and factors
• Application SWOT–AHP
analysis method
• Calculating priorities of
• Inﬂuence of SWOT
groups are identiﬁed
and visualized350 B. Ramezanpour et al. / V
Expression systems may  be used to express genes encoding
mmunogens of pathogens in order to directly induce protective
mmune responses in the human or animal host [7,8]. Vectors
pplied for this type of vaccine delivery include plasmid DNA,
NA, viral and bacterial vectors [7]. Several viral vector-based vac-
ine platforms exist, such as adeno-, pox-, parainﬂuenza-, and
lphavirus-based expression systems. Those and the others allow
he establishment of vaccines for heterologous pathogens [2,7,9]
nd all have their inherent advantages and disadvantages.
In the recent decades recombinant poxviruses of mammals and
irds have shown potential as platforms for the development of
accines that induce protective immunity against various infec-
ious and neoplastic conditions of humans and animals [1,10,11].
espite these supportive data and the apparent potential of
oxvirus-based platforms and their current use in animal vaccines,
here is still no recombinant poxvirus based vaccine registered for
se in humans [12]. Nevertheless, several incremental improve-
ents, such as techniques allowing for better quantitative and
ualitative target antigen expression characteristics, prime-boost
egimens, as well as viral vector manufacturing and puriﬁcation
echnology, justify the expectation that several poxvirus vector-
ased vaccine candidates for humans are approaching their ﬁnal
tages of development [1,13,12].
Modiﬁed vaccinia virus Ankara (MVA) is among the most
dvanced and well-characterized recombinant vaccine vectors cur-
ently in human clinical trials [14]. MVA  is a highly attenuated strain
f vaccinia virus, originating from chorioallantois membrane pro-
uced vaccinia virus Ankara after more than 570 serial passages in
rimary chicken embryo ﬁbroblasts (CEF). This serial passaging of
VA resulted in a loss of virulence and immune evasion genes as
ell as its ability to replicate in most mammalian cells [15,16]. Cur-
ently, European Medicine Agency (EMA) has approved a vaccine
gainst smallpox containing a non-replicating live form of the MVA
irus, which implies effectiveness and safety of this vaccine plat-
orm technology as an entity suitable for addressing a wide variety
f infectious diseases [17,18].
Altenburg et al. elaborate on the advantages and disadvantages
f MVA  as viral vector platform for vaccines against inﬂuenza and
ther viral respiratory diseases in their reviews. They describe
nique properties of MVA  as viral vector vaccine including its
iological safety proﬁle, relative easy production process for large-
cale manufacturing, and potential to efﬁciently express a plethora
f foreign genes either alone or in combination enabling the use
f MVA  as a versatile and multivalent vaccine [11,17,19]. More-
ver, MVA  has immunostimulatory capacities to induce protective
mmune responses against many infectious agents. In particular
argeting the innate in addition to the adaptive immune system
bviates the use of an adjuvant [11]. Replication deﬁciency of
VA  is conﬁrmed in various in vivo mammalian models includ-
ng animals with severe immunodeﬁciencies [17]. Furthermore,
ecombinant MVA  viruses can be used under conditions of biosafety
evel 1 in most countries. These features provide advantages com-
ared to replication competent poxvirus vectors and other viral
ectors [17].
Pre-existing anti-vector immunity may  hamper the effective-
ess of vectored vaccines. Nonetheless, also in the presence of
re-existing anti-vector immunity, protective immunity against
or instance inﬂuenza could be induced [10,11,17]. Although sev-
ral inﬂuenza virus proteins have been shown to induce different
evels of protective immunity, in the current study we  took the
pproach that an MVA  based vaccine against pandemic inﬂuenza
hould primarily express the hemagglutinin (HA) gene [20–24].Limitations associated with other production platforms also
pply to MVA  viral vectored vaccine candidates. Considering that
VA  has the potential to express multiple foreign antigens of inter-
st, each new recombinant MVA  virus is considered a new biologicale 33 (2015) 4349–4358
entity and thus requires proper quality assessment. Furthermore,
heterologous prime-boost vaccination strategies will complicate
the regulatory approval process [17]. These issues need to be
addressed prior to successful implementation of this platform for
use against pre-pandemic and pandemic inﬂuenza and other new
emerging pathogens. More data on efﬁcacy in humans would also
contribute to success of this platform.
In the present study we  have evaluated the commercial poten-
tial of MVA  vector-based vaccine technology for pre-pandemic
and pandemic inﬂuenza by approaching key opinion leaders
(KOLs) in the ﬁeld of inﬂuenza vaccine development, in order to
obtain a balanced view on its strengths, weaknesses, opportuni-
ties, and threats using the SWOT–AHP combined analytic method
[25–27]. Application of AHP method helps construct a multi-criteria
decision-making process, identify decision-making factors, and
determine the reciprocal importance of these factors [28]. AHP
method provides the possibility to quantify and prioritized sub-
jective, qualitative, and intangible factors into numeric values.
Moreover, this approach is an effective decision-making method
especially when subjectivity might exist [26].
In doing so we provide an empirically validated contempo-
rary industry view of MVA  as a vaccine technology platform. We
demonstrate that MVA  is considered a suitable platform for vac-
cine development, and argue that there is a future for MVA  based
vector platforms to develop not only preventive, but also thera-
peutic vaccines to address unmet public health needs in the ﬁeld
of infectious diseases.
2. Methodology
The methodology used is built-up into three data collection
moments. First, collecting background information from the liter-
ature, which subsequently enabled us to develop a balanced set
of interview questions. Next, quantiﬁcation of the qualitative data
generated from interviews with KOLs by means of SWOT–AHP
application. Finally, drawing conclusions by integrating the two
previous steps (Table 1).
2.1. Literature reviews and interviews
A literature study was conducted to gain more insight into the
MVA  platform and its potential for inﬂuenza vaccine development,main groups and each
factor within SWOT
•  Overall factor weight,
quantiﬁed and ranked
accine 33 (2015) 4349–4358 4351
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Internal  Analysis External  Analysis
Strengths Weaknesses Opportunities Threats
8 3 5 6
ENVIRONMENT SCAN
SWOT MATRIX
Fig. 1. SWOT analysis framework. Environmental scan provide two different anal-
techniques to obtain “”. “” is called an “eigenvalue”.  is calcu-
lated by dividing each new vector by the corresponding eigenvector
element. The mean of these values is the estimated max. If the
pairwise comparisons are consistent, max = n.
Table 2
AHP scale. Pairwise comparison scale.
Intensity of importance Deﬁnition Explanation
1 Equal importance Two activities contribute
equally to the objective
3  Moderate
importance
Experience and judgement
slightly favour one activity
over another
5 Essential
importance
Experience and judgement
strongly favour one activity
over another
7 Very strong
importance
An activity is favoured very
strongly over another; its
dominance demonstrated in
practice
9 Extreme
importance
The evidence favouring one
activity over another is of theB. Ramezanpour et al. / V
ntervention strategies. In order to determine SWOT of the MVA
latform for inﬂuenza vaccines, semi-structured interviews with
OLs were performed.
Fifty out of a total number of sixty-two (80%) articles that were
elected based on topic relevance were published after 2010. Only
hirteen (20%) did not meet this criterion. This study used a combi-
ation of Pubmed, Google Scholar, ScienceDirect, Web  of Science,
pplying relevant search terms on the subject including virus vec-
ored vaccine, modiﬁed vaccinia virus Ankara (MVA), inﬂuenza
irus, pre-pandemic and pandemic vaccine, vaccine technology
latform, and vaccine production platform.
.1.1. Interview participants
KOLs, who include a range of inﬂuential individuals with exten-
ive knowledge and experience in the ﬁeld of inﬂuenza (e.g. US
epartment of Health and Human Services (HHS), CEOs and Senior
anagers from large companies in the ﬁeld of inﬂuenza, World
ealth Organization (WHO), National Institute of Infectious Dis-
ases (NIAID)), wish to remain anonymous due to conﬁdentiality
oncerns. Participants were approached to contribute in interviews
epresenting industry, (non) governmental, and public research
nstitutions. This selection was based on their expertise in the
nﬂuenza vaccine ﬁeld. Twenty-four out of ninety KOLs agreed to
articipate in the study (response rate of approximately 30%). In
his research we subdivided them into two groups: industry and
on-industry. Eighteen participants from industry and six, non-
ndustry participants contributed in the study.
.1.2. Exploratory interviews
The participants were contacted, informed about the nature of
he study, and invited to take part. Two pilot interview sessions
ere conducted prior to implementation of 60 min  semi-structured
nterviews.
.1.3. Interview questions
Interview questions (Appendix 5 (supplementary materials))
ere developed focusing on the inﬂuenza ﬁeld, in particular
VA  virus vector vaccines, and their implementation potential.
n essence, the interviews were designed to gather data on how
OLs perceive the current pandemic vaccine ﬁeld, possibilities to
ncrease the commercially attractiveness and public health value of
nﬂuenza vaccines, reciprocal competition in the inﬂuenza vaccine
arket, and SWOT of MVA  platform for inﬂuenza vaccines.
.2. SWOT analysis
SWOT analysis is a commonly used business analysis tool to
valuate external and internal environmental factors, which could
mpact the strategic planning process. The purpose of SWOT appli-
ation in decision-making is to develop and implement a strategy
esulting in a good ﬁt between internal and external factors. Inter-
al factors to the theme are usually classiﬁed as strengths and
eaknesses, and those external to the theme are classiﬁed as
pportunities and threats (Fig. 1) [25–27,29].
.3. AHP analysis
AHP is a multi-criteria decision analysis tool that helps express
he general decision process by deconstructing a complicated prob-
em into a multilevel hierarchical structure [28]. Furthermore, AHP
ethod is applied as prioritization mechanism to accomplish pair-
ise comparison of factors representing the relative importance of
he criteria determined by the joint judgments of the experts. The
eam of experts provides their preferences by comparing two  given
actors. The question is which of the two factors has a greater valueysis;  internal factors and external factors. This study comprises; Internal factors:
strengths (8 factors), weaknesses (3 factors); External factors: opportunities (5 fac-
tors), threats (6 factors).
and how much. The comparisons are made using a scale of abso-
lute numbers that represents which of the two factors has a greater
weight in the choice and how much. In AHP, pairwise comparisons
are based on a standardized comparison scale of 1–9 (Table 2).
The whole number is entered in its appropriate position and its
reciprocal in the transpose position [28,30,31].
Pairwise comparisons are separately made for each SWOT
group. In the next step relative weights of factors are calculated
where W1, W2,. . .,  Wn are the weights obtained by the compar-
isons. Subsequently, multiply together the elements in each row
of the matrix, and then take the nth root of that product. “W” is
called an “eigenvector” of order n. The sum of the nth roots is used
to normalize the eigenvectors to add to 1 (Table 5).
W1
W1
W1
W2
. . .
W1
Wn
W2
W1
W2
W2
W2
Wn
...
...
...
Wn
W1
Wn
W2
. . .
Wn
Wn
Each eigenvector is normalized by multiplying the matrix of judg-
ments by eigenvectors of each element, providing a new vector.
Relative importance values are obtained by using the eigenvaluehighest possible order of
afﬁrmation
2, 4, 6, 8 Intermediate
values
When compromise is needed
between two
4352 B. Ramezanpour et al. / Vaccine 33 (2015) 4349–4358
Table 3
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Strengths Weaknesses Opportunities Threats
S1
S2
Sn
W1
W2
Wn
O1
O2
On
T1
T2
Tn
GOAL
(S) (W) (O) (T)
T
A
e
sn: 1 2 3 4 5 6 7 8 9 10
RI 0.00 0.00 0.58 0.90 1.12 1.24 1.32 1.41 1.45 1.49
The quality of the AHP is related to the consistency of the pair-
ise comparison judgments. Therefore, it is important to judge the
onsistency of the decision-making. The Consistency Index (CI) is
alculated using the following equation:
I = max − n
n − 1
onsistency Ratio (CR) can conclude whether the evaluations are
ufﬁciently consistent.
According to Random Index (RI), if the number of CR exceeds
he value of 0.1, the evaluation procedure has to be repeated to
mprove consistency (Table 3). A CR of 0.1 or less is generally stated
o be acceptable. The AHP method applied in this study is based on
esearch method developed by Saaty [28,30] and used by Görener,
ee, and Kahraman [26,27,32].
R = CI
RI
.4. SWOT–AHP analysis model
Here, we provide quantitative means for SWOT analysis. One
f the main limitations of the classical SWOT analysis is that the
mportance of each factor cannot be quantiﬁed. Therefore, it is dif-
cult to assess the mutual effect on factors and each factor on the
ecision [26]. In order to circumvent this inadequacy, the SWOT
ramework is designed into a hierarchic structure and the model is
ntegrated and analyzed using the AHP.
In this study SWOT factors are identiﬁed by KOLs from industry,
non) governmental, and public research institutions. All pairwise
omparisons are accomplished by the joint judgement of a team of
xperts representing the relative importance of the criteria. Expert
eam is constituted from four members with expertise in the ﬁeld
f inﬂuenza and analysis skills [26].
Quantiﬁcation of the SWOT frame via AHP provides the opportu-
ity to calculate priorities for the groups and factors analyzed. The
nconsistency ratios represent whether the experts are consistent
able 4
lternative inﬂuenza pandemic vaccine production methods beyond phase I. Pro’s and co
ssential antigens (e.g. hemagglutinin (HA) and neuraminidase (NA)) that stimulate immu
ystem  for genes/antigens to generate desired immune response.) [33–53].
Alternative production methods Advant
1. Whole inactivated virus (WIV) • Estab
2. Split virus • Estab
•  Less s
3. Sub-unit (HA/NA/...)
Inﬂuenza virus derived • Estab
• Less s
Split Vi
Vector derived (e.g. baculovirus) • Rapid
• Less s
VLP • Rapid
• Less s
4. Vectored subunit (e.g. Adenovirus) • High d
• Cross
5. Live-attenuated • Estab
•  Low/s
•  Needl
6. DNA vaccines • No prFig. 2. Hierarchical structure of the SWOT  matrix.
with themselves while assigning the scores in the pairwise compar-
ison matrixes. This method is used to determine relative priorities
on absolute scales from both discrete and continuous paired com-
parisons in multilevel hierarchic structures. Furthermore, AHP is
an effective decision-making method especially when subjectivity
might exist [26].
In this study, the result of the AHP–SWOT model application
was divided into three parts: goal, the SWOT groups and the factors
included within each SWOT group (Fig. 2). The goal of this study is
identiﬁcation and quantiﬁcation of MVA’s strengths, weaknesses,
market opportunities, and potential threats to provide insight into
the potential and critical issues that impact the overall success of
implementation of this novel platform.
3. Results
Results of the literature study on the MVA  platform and its
potential for inﬂuenza vaccine development in comparison to
alternative inﬂuenza pandemic vaccine production methods are
presented in Table 4.Analyzing the SWOT groups and factors from the interview
transcripts resulted in 8 strengths, 3 weaknesses, 5 opportunities,
and 6 threats tabulated in a SWOT matrix, as presented in Table 5.
Subsequently, quantiﬁcation of the SWOT group by means of AHP
n’s in relation to the MVA  platform. (3. Sub-unit: inﬂuenza virus-derived; puriﬁed
ne system, vector-derived; expression system for gene encoding antigens/delivery
ages Disadvantages Refs.
lished technology • Side-effects
• High dose/Adjuvant
required
[33–36]
lished technology
ide-effects compared to WIV
• High dose/Adjuvant
required
[33,37]
lished well-deﬁned technology
ide-effects compared to WIV  and
rus
• High dose/Adjuvant
required
[38–40]
 production
ide-effects
• High dose/Adjuvant
required
[41]
 production
ide-effects
• Complex technology
• High level
puriﬁcation
[42–44]
ose production possibility
-reactive
• Pre-existing
interfering immunity
[38,45,46]
lished technology
ingle dose required
e free application
• Temperature
sensitive
[47,48]
e-existing interfering immunity • Limited efﬁcacy [38,51–53]
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Table  5
SWOT matrix; importance degrees within SWOT group. Comparing the importance degrees of the SWOT group, strengths appear to be the most outstanding property of
MVA  (example; strengths from SWOT group: product of the row; 20, nth root; 2.12, sum of all nth roots; 4.59, importance degree; 2.12/4.59 = 0.46).
Non-adjuvanted MVA is commercially more attractive, due to safety 
concerns of adjuvantsS1
Good immunogenicity and broad protective e fficacy of MVA offer 
excellent commercial attractiveness (Including convincing human 
data)
S2
Non-adjuvanted MVA provides more public health valueS3
High immunogenicity and reasonable pricing make MVA 
commercially more attractiveS4
Public health value of M VA is sustainable, due to high value of 
immunogenicity in public health point of viewS5
MVA's commercially attractiveness is sustainable. 
MVA is an excellent backbone, safe and e ffectiveS6
MVA has a high public health value if equally e ffective and safe 
as current vaccinesS7
Good immunogenicity and broad protective e fficacy of MVA 
provide public health value (Convincing data, vaccine 
superiority for scientific community and public)
S8
Strengths
MVA can be presented as pre-pandemic and mock-up vaccines. 
Mock-up can be employed for regulatory construct to make 
advance agreements with government
O1
Competition of other non-adjuvanted H5N1 vaccines is 
not relevant, influenza market is la rgeO2
Non-adjuvanted vaccines o ffer more opportunities in 
some markets (e.g. USA)O3
Regulatory approval of non-adjuvanted M VA will make it 
commercially more attractiveO4
Sustainability of MVA's commercial attractiveness depends on 
qualit y, availability and costO5
Opportunities
Low public health value, doubts about vector vaccines and 
anti-vector immunityW1
MVA's commercial attractiveness might be very sustainable, but 
without seasonal production facility, no one is going to bear the 
development costs
W2
Non-adjuvanted vaccines: offer fewer doses, fewer people get 
vaccinated, slower market reachW3
Weaknesses
Commercial attractiveness of non-adjuvanted MVA is 
antigen dependentT1
Public health value of non-adjuvanted M VA depends on 
vaccine acceptance by public (getting vaccinated with 
another virus (MVA)) and sufficient coverage
T2
Adjuvanted vaccines offer more dosesT3
Commercial attractiveness of non-adjuvanted MVA depends 
on public acceptance/perceptionT4
Adjuvant can make a difference between protection and no 
protection and provides cross-reactivityT5
Many competing products are in late stage clinical trials. 
MVA has to have profound competitive advantages to 
compete on the same market for same customers
T6
Threats
Strengths
Strengths
Weakness
SWOT
groups Opportunities Threats
Weakness
Opportunities
Threats
5.000 2.000 2.000
0.200 0.500 0.500
0.500 2.000 1.000
0.500
00
2.000 1.000
Importance
Degrees
0.461
0.103
0.218
0.218
S:
46%
W:
10%
O:
22%
T:
22%
o
f
g
g
e
s
e
t
eCR = 0.002 1.0
ffers the possibility to calculate the priorities for each group and
actors within these groups. Pairwise comparisons of the SWOT
roups are determined by asking the question of which of the two
roups has a greater weight in the choice and how much. Each pref-
rence is converted into a numeric value based on 1–9 Saaty’s AHP
cale [28]. All pairwise comparisons were performed by a team of
xperts in the ﬁeld. Multiplying the entries in each row of the matrix
ogether and then taking the nth root of that product provide the
igenvector (importance degree). Subsequently, the nth roots aresummed and the sum is used to normalize each eigenvector num-
ber to add to 1 (Example strengths from SWOT group (Table 5):
product of the row; 20, nth root; 2.12, sum of all nth roots; 4.59,
importance degree; 2.12/4.59 = 0.46.).
Table 5 demonstrates that the strengths far outdistance (46%)
the opportunities, threats, and weaknesses of MVA  platform,
respectively. The strengths are 4.48 times more important than
weaknesses (0.461/0.103) and 2.11 times more important than
opportunities and threats (0.461/0.218).
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Strengths
S1
W1
O1
O2
O3
O4
O5
W2
W3
S2
S3
S4
S5
S6
S7
S8
Weaknesses
Opportunities Threats
T1
T2
T3
T4
T5
T6
F
o
w
3
•
•
•
•
•
•
•
•
3
•ig. 3. The priority degree of the categorized factors from strengths, weaknesses,
pportunities and threats. S1/S2–W1–O1–T1/T2 are the most inﬂuential factors
ithin the SWOT groups.
.1. Descriptive results, strengths
The eight main strengths are determined as follows:
Non-adjuvanted MVA  is commercially more attractive. This is due
to safety concerns that adjuvants still raise. The beneﬁts from
adjuvants have to be balanced with the risks of adverse reactions.
Good immunogenicity and broad protective efﬁcacy of MVA offer
excellent commercial attractiveness. Convincing human clinical tri-
als data have to be provided.
Non-adjuvanted MVA  provides more public health value. This is due
to safety concerns.
High immunogenicity and reasonable pricing make MVA  commer-
cially more attractive. Although the vaccine market is competitive,
providing vaccines with high immunogenicity and reasonable
pricing creates a competitive advantage in the market.
Public health value of MVA  is sustainable. This is due to high value
of immunogenicity in a public health point of view.
MVA’s commercially attractiveness is sustainable. MVA is an excel-
lent backbone, safe, and effective.
MVA  has a high public health value. In case of equal safety and
effectiveness as current vaccines.
Good immunogenicity and broad protective efﬁcacy of MVA provide
public health value. Convincing data have to be provided on vac-
cine superiority for scientiﬁc community and public.
.2. Descriptive results, weaknessesThe three main weaknesses are determined as follows:
Low public health value. Doubts are expressed concerning vector
vaccines and anti-vector immunity.e 33 (2015) 4349–4358
• MVA’s commercial attractiveness might be very sustainable, but
without seasonal production facility, no one is going to bear the
development costs.
• Non-adjuvanted vaccines: offer fewer doses, fewer people get vacci-
nated, slower market reach.
3.3. Descriptive results, opportunities
The ﬁve main opportunities are determined as follows:
• MVA can be presented as pre-pandemic and mock-up vaccines.
Mock-up can be employed for regulatory construct to make
advance agreements with government.
• Competition of other non-adjuvanted H5N1 vaccines is not relevant.
Inﬂuenza market is large. There are still opportunities for entry
and growth for vaccines companies.
• Non-adjuvanted vaccines offer more opportunities in some markets
(e.g. USA). This is due to strict regulations for the human use of
adjuvants than those applied for veterinary vaccines.
• Regulatory approval of non-adjuvanted MVA  will make it commer-
cially more attractive.
• Sustainability of MVA’s commercial attractiveness depends on qual-
ity, availability, and cost.
3.4. Descriptive results, threats
The six main threats are determined as follows:
• Commercial attractiveness of non-adjuvanted MVA  is antigen
dependent. Dependent on the virulent of emerging pandemic
inﬂuenza virus.
• Public health value of non-adjuvanted MVA depends on vaccine
acceptance by public and sufﬁcient coverage. It is challenging to
convince people to get vaccinated against inﬂuenza virus with
another virus (MVA).
• Adjuvanted vaccines offer more doses.
• Commercial attractiveness of non-adjuvanted MVA  depends on pub-
lic acceptance/perception.
• Adjuvant can make a difference between protection and no protec-
tion and provides cross-reactivity.
• Many competing products are in late stage clinical trials. MVA  has to
have profound competitive advantages to compete on the same
market for same customers.
Subsequently, AHP was  used to perform pairwise comparisons
to derive relative importance degrees of the factors within each
group. As demonstrated in Table 6, in the comparison matrix the
sum of vector is 1, and the vector represents the relative importance
among the factors compared. Comparison of various factors within
the strengths group illustrates that S1 and S2 are considered to be
equally inﬂuential in this group. Table 6 exempliﬁes the comparison
matrix applied to determine the importance degrees of each SWOT
group. The priority degrees of the SWOT factors within the groups
have been visualized in Fig. 3. The most inﬂuential factors within
the SWOT groups are: S1/S2, W1,  O1, T1/T2.
Last, the overall priority scores of the SWOT factors were cal-
culated by multiplying the importance degrees of SWOT groups,
as shown in Table 5, by the priority degrees of the factors
within the groups as shown in Table 7. The overall priorities of
the most inﬂuential SWOT factors were: strengths, 0.111 (e.g.
0.461 × 0.241 = 0.111); weaknesses, 0.043; opportunities, 0.085;
threats, 0.045. The ﬁnal stage was  to calculate the consistency ratio
in order to ﬁnd out how consistent the judgments have been rela-
tive to large samples of purely random judgments. The number 0.1
is the accepted upper limit for consistency ratio (CR) [26]. The ﬁnal
CR of all the pairwise comparisons is within the limit.
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Fig. 4 visualizes the graphical interpretation of overall priority
of the SWOT group within the ﬁeld of MVA  according to the KOLs.
46% of the MVA  market is assigned to the strengths of this plat-
form. Opportunities, threats, and weaknesses constitute 22%, 22%
and 10% of the market, respectively.
4. Discussion
This study provides unique quantitative data to support stud-
ies suggesting that MVA  meets the unmet needs of the current
vaccine platform for pandemic inﬂuenza vaccine development
[1,10–12,14,15]. The ﬁndings show the following ranking of each
SWOT group priority: strengths (importance degree (ID), 46.1%),
opportunities and threats (ID, 21.8%), and weaknesses (ID, 10.3%).
These results indicate that the KOLs evaluated strengths of the
MVA  platform outweigh weaknesses, opportunities, and threats.
This indicates that safety, good immunogenicity, and broad pro-
tective efﬁcacy are overall the most important considerations for
successful implementation of this vaccine platform. Furthermore,
literature describes various (pre) clinical trials and studies demon-
strating immunostimulatory capacities that make MVA  induce
protective immune responses against many infectious agents
[11,15,19,20,54,55].
This study was  designed to explore the commercial potential of
the MVA  platform for the development of novel generation pan-
demic inﬂuenza vaccines. Results from both literature study and
KOL’s perspectives helped us understand the current strengths,
weaknesses, opportunities, and threats for implementation of this
platform. Furthermore, the quantiﬁed data helped in assessing the
reciprocal effect within each SWOT group and effect of each factor
within each group on the strategic planning process.
Since conversion from qualitative to quantitative scales is based
on untested assumption, critics argue the existence of possible
inconsistency in pairwise comparisons. The use of pairwise com-
parison, however, simpliﬁes the expert’s judgmental tasks to focus
each time on a part of the issue. Furthermore, AHP method auto-
matically carries out an inherent inconsistency check by requiring
more judgments to be made than it is needed to establish a set
of weights [56,57]. Critics have also questioned whether the AHP
method can represent KOL’s preference given the quantitative rep-
resentations of these judgments and the mathematical method
applied. It is important to realize that deconstructing important fac-
tors during decision-making process allows simplifying a complex
problem into a multi-criteria decision-making, which consequently
contributes to the main purpose of any decision; creating insights
and understanding rather than ﬁnding the right answer.
Literature has widely acknowledged that MVA has advantages
over currently used vaccines and vaccine platforms in development
4356 B. Ramezanpour et al. / Vaccine 33 (2015) 4349–4358
Table 7
Inconsistency ratio of the SWOT group and priority of the factors within the groups have been illustrated. Overall priority of each factor is resulted from multiplying the
priority of the group with priority of the factor within the group.
S1
S2
S3
S4
S5
S6
S7
S8
Strengths
T1
T2
T3
T4
T5
T6
Threats
O1
O2
O3
O4
O5
Opportunities
W1
W2
W3
Weaknesses
Inconsistency 
Ratio
Priority of the factor 
within the group
Overall priority 
of the factor
SWOT factors
Non-adjuvanted MVA is commercially more attractive, due to safety concerns 
of adjuvants
Good immunogenicity and broad protective efficacy of MVA offer excellent 
commercial attractiveness (Including convincing human data)
Non-adjuvanted MVA provides more public health value
High immunogenicity and reasonable pricing make MVA commercially 
more attractive
Public health value of MVA is sustainable, due to high value of immunogenicity 
in public health point of view
MVA's commercially attractiveness is sustainable. 
MVA is an excellent backbone, safe and e ffective
MVA has a high public health value if equally e ffective and safe as current 
vaccines
Good immunogenicity and broad protective e fficacy of MVA provide public health 
value (Convincing data, vaccine superiority for scientific community and public)
MVA can be presented as pre-pandemic and mock-up vaccines. Mock-up can be 
employed for regulatory construct to make advance agreements with government
Competition of other non-adjuvanted H5N1 vaccines is not relevant, influenza 
market is large
Non-adjuvanted vaccines o ffer more opportunities in some markets (e.g. USA)
Regulatory approval of non-adjuvanted M VA will make it commercially 
more attractive
Sustainability of MVA's commercial attractiveness depends on qualit y, 
availability and cost
Low public health value, doubts about vector vaccines and anti-vector 
immunity
MVA's commercial attractiveness might be very sustainable, but without 
seasonal production facility, no one is going to bear the development costs
Non-adjuvanted vaccines: offer fewer doses, fewer people get vaccinated, 
slower market reach
Commercial attractiveness of non-adjuvanted MVA is antigen dependent
Public health value of non-adjuvanted M VA depends on vaccine acceptance by 
public (getting vaccinated with another virus (M VA)) and sufficient coverage
Adjuvanted vaccines o ffer more doses
Commercial attractiveness of non-adjuvanted MVA depends on public 
acceptance/perception
Adjuvant can make a di fference between protection and no protection and 
provides cross-reactivity
Many competing products are in late stage clinical trials. MVA has to have profound 
0.005 0.241 0.111
0.111
0.047
0.039
0.039
0.039
0.039
0.036
0.043
0.034
0.027
0.413
0.327
0.260
0.241
0.102
0.085
0.085
0.012 0.388 0.085
0.045
0.039
0.027
0.022
0.205
0.179
0.125
0.103
0.017 0.206 0.045
0.045
0.036
0.036
0.028
0.206
0.164
0.164
0.130
0.085
0.085
0.078
0.046
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wcompetitive advantages to compete on the same market for same customers
1,15,19,58]. Under the strength group, immunogenicity related
actors were rated as the most inﬂuential strength to be consid-
red with an approximately 0.5 total priority of factors within this
roup and a 0.23 as overall priority. Subsequently, immunogenic
apabilities of MVA  without the need of an adjuvant are the sec-
nd most inﬂuential subject in this group with a 0.34 priority rate
ithin the group and a 0.16 overall priority rate. Finally, factors
elated to safety and effectiveness of this platform are considered
o be important assets of this platform with a priority rate of 0.17
ithin the groups and an overall priority rate of 0.078. From a KOL’s0.0280.130
perspective, factors related to immunogenicity and without an
adjuvant need, increase the commercial attractiveness and public
health value of this platform. Moreover, factors related to immuno-
genicity and safety and effectiveness of this platform increase its
sustainability value in the vaccine market. According to the KOLs,
providing human data on MVA’s capability to induce enhanced
immunogenicity and broad protective efﬁcacy will further increase
commercial attractiveness of this platform.
Furthermore, these properties provide the opportunity of get-
ting regulatory approval in particular in some markets where
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djuvants are not being accepted due to safety concerns. Indus-
ry representatives indicate that using the MVA  platform creates
pportunity to invade other as yet unreached markets. Fur-
hermore, the use of mock-up dossiers approved for regulatory
uthorities may  help in negotiating advance agreements with gov-
rnments, ensuring industries future cash ﬂow. In case of novel
accines, safety of the vaccine is the ﬁrst consideration. Safety data
rom the MVA’s clinical trials shows great promise [16]. At the same
ime, KOLs emphasize the fact that MVA’s capability to induce such
mmunogenicity could be largely dependent on the antigen used.
ccording to the literature, much research is dedicated to emerg-
ng novel and alternative vaccine strategies over the last decade.
esearch in vaccine ﬁeld emphasizes emergence of the poxviral
accine platforms as a profound delivery platform [1,11,59].
KOLs indicate that one of the main challenges that MVA-
ectored vaccines are facing is the acceptance of this platform by
he lay public in the vaccine ﬁeld. This challenge is contradicted
y our literature search results. Application of poxvirus vectors for
he expression of foreign genes of interest is becoming more attrac-
ive than other viral vectors [16,17]. Despite the fact that there are
o licensed poxvirus vector-based human vaccines on the market
et, there is an increasing amount of clinical trials of poxvirus vec-
or vaccine candidates for infectious diseases [12]. This discrepancy
ight be an indication that there is a perception change towards
he vector vaccines. In this context it is important to recognize that
VA, as a modiﬁed live form of the vaccinia virus, has already been
pproved as a backbone vector system in a vaccine against smallpox
60].
A key unmet need of the current inﬂuenza vaccines are speed
nd scalability resulting in production of sufﬁcient vaccine dosages
ithin the required time frame. KOLs indicate the same unmet
eed as one of the threats MVA  might be encountering. Recently,
arge-scale production of MVA  has been shown to be possible
or four million doses of non-recombinant MVA-smallpox-vaccine.
oreover, two companies have developed cell lines suitable for
VA manufacturing to avoid the need for embryonated eggs [10].
on-industry representatives consider issues related to quality,
afety, availability, and reasonable pricing of vaccines essential for
VA’s commercial sustainability. Moreover, they indicate that pub-
ic vaccine acceptance will likely be a key factor to simultaneously
ncrease public health value and commercial attractiveness of the
VA  platform.
This study indicates that the sustainability of the MVA  plat-
orm can be assured by exploring this platform for use in both
easonal and pandemic inﬂuenza as well as other infectious dis-
ases in particular those caused by newly emerging viruses [10].
ome KOLs stress the challenge of having many competitors in
he inﬂuenza market ﬁghting for the same costumers. In 2011,
he global inﬂuenza vaccine market was valued at over three and
 half billion dollars and is predicted to grow annually about 6%
ver the next seven years to reach over ﬁve billion dollars in
018 [61].
The most favourable feature of this platform is its proven
mmunogenicity, broad protective efﬁcacy without the require-
ent of an adjuvant, and its relatively easy scalability which make
VA the vaccine platform of choice for many so far unmet vaccine
eeds. Thus, MVA’s speciﬁc properties stress the great potential
f this platform. Although the public acceptance of such vaccines
an be challenging, providing safety data in human trials could
esult in a change in perception. The inﬂuenza market offers sufﬁ-
ient opportunities for MVA  to be implemented as a novel vaccine
latform with broad protection against seasonal and pandemic
nﬂuenza viruses. Despite the fact that poxviral vector platform
olds a great promise for market implementation, more collabo-
ation is required between academia, vaccine industries, and the
egulatory authorities [11].
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